4-Hydroxyestrone + 4-Hydroxyestradiol [4-OH(E1+E2)]

Your body converts estrone and estradiol into several families of breakdown products. This result combines 4-hydroxyestrone and 4-hydroxyestradiol in liquid urine collected over 24 hours. These compounds have attracted interest because laboratory experiments link further chemical changes in them to DNA damage.

The result is reported relative to urinary creatinine, in mcg/g creatinine. Creatinine is a waste product used to account for urine concentration. The number therefore describes the pair's concentration after this adjustment; it isn't an absolute amount excreted per day.

This is a research-stage marker. Human studies have examined related estrogen measurements and cancer risk, but the combined urine result has no validated cancer-risk threshold, established optimal level, or demonstrated benefit for screening or guiding treatment.

How Your Body Makes and Processes This Pair

Estrogen metabolism includes routes called 2-hydroxylation, 4-hydroxylation and 16-hydroxylation. The numbers identify where a chemical change happens on the estrogen molecule. This pair belongs to the 4-hydroxylation route.

An enzyme called COMT helps convert 4-hydroxy estrogens into 4-methoxy estrogens. That conversion reduces the material available to form quinones. Quinones are reactive compounds that can attach to DNA. In experiments with cultured human breast cells, blocking COMT increased the formation of compounds attached to DNA.

Those experiments help explain why researchers study this pathway. They don't establish how much DNA damage corresponds to a particular urine result. Urinary levels reflect production, further processing and excretion across the body, and can differ from concentrations inside breast tissue. In a small study of nine women with breast cancer, no 4-pathway compounds were detected in breast tissue, even though 4-hydroxyestrone was found in their urine. Methoxy output also cannot establish that all potentially harmful reactions have been prevented.

What Breast Cancer Studies Have Found

The studies measure several different things. Many widely cited studies measured 4-hydroxyestrone alone, without 4-hydroxyestradiol. Their broader 4-pathway totals also included methoxy forms. Some used serum, others used spot urine. None of those measurements is identical to this combined result from a 24-hour urine collection.

These findings don't support treating every higher result as harmful or every lower result as protective. The relationship depends on what was measured, the comparison used and the population studied. Even associations involving ratios cannot establish how quickly an enzyme works or whether changing that ratio would prevent cancer.

The 2-pathway is also sometimes described as uniformly protective. Several prospective studies found lower risk when 2-pathway levels were high relative to parent estrogens. A later Nurses' Health Study analysis looked at circulating 2-pathway levels themselves, adjusted for estradiol, and found higher risk at higher levels. The two approaches measure different things, so the results conflict without being exact opposites. That later analysis reported results for the 2- and 16-pathways, not the 4-pathway.

Estrogen-DNA adducts are compounds formed when estrogen-derived molecules attach to DNA. A Taiwanese study of 367 women found higher plasma adduct ratios in a group that combined breast cancer with certain noncancerous breast conditions involving extra cell growth, particularly before menopause. It compared women with existing disease with controls. It did not show that this urinary metabolite pair predicts future cancer.

Dense Breasts and Other Areas of Research

In a study of 194 postmenopausal women assessed at one point in time, the 2-, 4- and 16-pathway-to-parent-estrogen ratios in urine were each associated with lower mammographic density. Most individual estrogen measurements were not associated with density. This was an exploratory association involving different measurements; the combined pair cannot determine whether you have dense breasts or how much risk density adds.

A study of 16 men found higher urinary levels of a DNA adduct derived from 4-hydroxyestrone in men with prostate cancer or benign urologic conditions than in healthy controls. That adduct is a different molecule from either compound measured here, and the study did not establish a useful screening test.

A study of 24 pregnant women found higher plasma 4-hydroxyestrone during labor in severe preeclampsia, along with changes in other estrogen metabolites. A larger urine study of 66 women with preeclampsia and 137 without found the opposite direction: about 20% lower 4-pathway and 2-pathway levels in mid and late pregnancy. Preeclampsia involves high blood pressure and can damage organs during pregnancy. Neither study validated this urine measurement for predicting or diagnosing the condition.

When Results Can Be Misleading

• Hormonal state: menstrual cycle phase, pregnancy and menopause affect estrogen metabolism. During pregnancy, the two compounds can change in different directions, so their sum can conceal changes in either one.
• Hormone medicines: contraception and hormone therapy can change the pattern. A different result while taking hormones does not by itself establish harmful processing or treatment safety.
• Collection problems: missed urine, incorrect collection times, blood contamination and improper storage can distort the sample. Creatinine adjustment means an incomplete collection does not always produce a predictably lower number.
• Kidney function and creatinine: changes in excretion or in the creatinine used for adjustment can affect interpretation independently of estrogen production.
• Low concentrations: LC-MS/MS can measure small amounts, but results near its detection limits are less certain. A result reported as below detection does not mean the compound is absent. Ratios become unreliable when the value used as the denominator is very small or below detection.
• Different tests: a result for 4-hydroxyestrone alone, a dried-urine result and this combined liquid-urine result are different measurements. Matching units alone does not make them interchangeable.